OasisLMS

AI is rapidly entering EP labs but its real test is whether it can standardize complex workflows and expand access to care. This roundtable separates hype from impact and explores how AI-enabled pathways can help find, refer, and treat the complex AF patients who make up the “untreated majority.” The discussion will also examine how reimbursement and coverage considerations influence the adoption, scalability, and patient access of these emerging technologies.